General Healthy(605186)2022-04-29 16:00Financial Performance - The company's operating revenue for Q1 2022 was ¥45,380,407.33, representing an increase of 11.19% compared to the same period last year[5]. - The net profit attributable to shareholders for Q1 2022 was ¥7,052,836.21, reflecting a growth of 10.65% year-over-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥7,012,578.93, which is an increase of 15.54% compared to the previous year[5]. - Total operating revenue for Q1 2022 was CNY 45,380,407.33, an increase of 11.5% compared to CNY 40,811,846.52 in Q1 2021[20]. - Net profit for Q1 2022 reached CNY 8,151,632.47, up 10.4% from CNY 7,378,978.29 in Q1 2021[21]. - Total operating costs for Q1 2022 were CNY 34,700,305.33, an increase of 10.4% from CNY 31,247,677.80 in Q1 2021[20]. Cash Flow and Assets - The company's cash flow from operating activities for Q1 2022 was negative at -¥60,500,250.05, indicating a significant cash outflow[5]. - Cash flow from operating activities showed a net outflow of CNY 60,500,250.05, worsening from a net outflow of CNY 51,838,262.91 in Q1 2021[25]. - Cash inflow from investment activities was CNY 50,044,046.16, while cash outflow was CNY 97,383,516.47, resulting in a net cash outflow of CNY 47,339,470.31[25]. - The total assets at the end of Q1 2022 were ¥1,064,942,116.69, a decrease of 5.72% from the end of the previous year[6]. - As of March 31, 2022, the company's total assets amounted to ¥1,064,942,116.69, a decrease from ¥1,129,566,326.94 as of December 31, 2021, reflecting a decline of approximately 5.7%[17]. - The company's current assets totaled ¥753,502,166.74, down from ¥850,687,666.75, indicating a decrease of about 11.4%[18]. - Cash and cash equivalents were reported at ¥361,024,063.75, a decrease of 23.0% from ¥468,916,999.82 at the end of 2021[17]. - The net increase in cash and cash equivalents for the period was -$107,892,936.07[26]. - The beginning balance of cash and cash equivalents was $468,416,999.82[26]. - The ending balance of cash and cash equivalents was $360,524,063.75[26]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 7,182[13]. - The largest shareholder, Dai Jianwei, holds 42.00% of the shares, totaling 57,113,219 shares[13]. Liabilities and Equity - The company's total liabilities were ¥81,272,014.66, down from ¥154,027,955.51, showing a significant reduction of about 47.3%[19]. - The equity attributable to shareholders increased slightly to ¥908,670,101.03 from ¥905,538,000.00, reflecting a marginal growth of 0.2%[19]. - The company reported a decrease in accounts payable from ¥32,498,762.59 to ¥12,428,953.12, a reduction of about 61.8%[19]. Research and Development - Research and development expenses increased by 31.45% during the reporting period, indicating a focus on innovation[11]. - Research and development expenses increased to CNY 5,569,046.07, representing a rise of 31.5% from CNY 4,236,733.51 in the previous year[20]. - The company has ongoing investments in new technologies and product development, although specific figures were not disclosed in the report[16]. Future Outlook - Future outlook includes potential market expansion strategies, although detailed projections were not provided in the current report[16]. Other Financial Metrics - The basic earnings per share for Q1 2022 was ¥0.05, unchanged from the previous year[6]. - Basic and diluted earnings per share remained stable at CNY 0.05 for both Q1 2022 and Q1 2021[22]. - The company reported a significant increase in cash received from sales, totaling CNY 58,036,517.48, compared to CNY 32,586,433.49 in the same period last year[24]. - The company experienced a credit impairment loss of CNY -2,524,893.79, worsening from CNY -1,388,038.97 in Q1 2021[21]. - The impact of exchange rate changes on cash and cash equivalents was -$53,215.71[26].